How CRISPR gene editing will treat diseases in future: Nobel-winning Intellia co-founder Jennifer Doudna
Gene-editing technology CRISPR reached a major milestone, completing its first systemic delivery as a medicine to a human body. CRISPR, or clustered regularly interspaced short palindromic repeats, effectively cuts genomes and slices DNA to treat genetic diseases.
Jennifer Doudna, who was awarded the 2020 Nobel Prize in chemistry for her work on CRISPR gene editing and is the co-founder of Intellia, recently told CNBC the evolution of the technology from the publication of her early work to clinical trials showing it to be effective in treating diseases in less than 10 years represents, “One of the fastest rollouts I think of technology from the fundamental, initial science to an actual application.”
“It’s largely because the technology comes at a moment when there’s enormous demand for genome editing, as well as a lot of knowledge about genomes,” Doudna said at the recent CNBC Global Evolve Summit in mid-June.
Read the full article here.
27 May 2022gMendel announces that the Innovation Fund Denmark has invested 200,000 Euro in gMendel's novel diagnostic technology.
11 May 2022Denmark’s vision to become a front-runner in the use of artificial intelligence reflects on the country’s national strategy for AI.
06 May 2022gMendel® announces CE marking for its Phivea® v1.0.0 platform, a novel screening technology for the detection of Klinefelter Syndrome.
26 Apr 2022Recent systematic review determines the prevalence of Klinefelter syndrome amongst transgender individuals presumed male at birth.